Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia

Current Opinion in Hematology

Volumn 4, Issue 4, 1997, Pages 233-241

  Rubnitz, Jeffrey E ^a   Pui, Ching Hon ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; ANTIMETABOLITE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; CHILDHOOD LEUKEMIA; GENE REARRANGEMENT; HIGH RISK PATIENT; HUMAN; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; PRIORITY JOURNAL; RELAPSE; REVIEW;

EID: 0030818160     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704040-00003     Document Type: Review

References (108)

1. Lilleyman JS: Acute lymphoblastic leukemia. Eur J Cancer 1997, 33:85-90.
2. Greaves MF: Aetiology of acute leukaemia. Lancet 1997, 349:344-349. The author discusses the potential causes of secondary leukemias, infant leukemia, and common childhood ALL.
3. Greaves MF: Infant leukaemia: biology, aetiology and treatment. Leukemia 1996, 10:372-377.
4. Petridou E. Trichopoulos D, Dessypris N, Flytzani V, Haidas S, Kalmanti M, Koliouskas D, Kosmidis H, Piperopoulou F, Tzortzatou F: Infant leukaemia after in utero exposure to radiation from Chernobyl [see comments]. Nature 1996, 382:352-353.
5. Darby SC, Roman E: Links in childhood leukaemia [news; comment]. Nature 1996, 382:303-304.
6. Parkin DM, Clayton D, Black RJ, Masuyer E, Friedl HP, Ivanov E, Sinnaeve J, Tzvetansky CG, Geryk E, Storm HH, et al.: Childhood leukaemia in Europe after Chernobyl: 5 year follow-up. Br J Cancer 1996, 73:1006-1012.
7. Ji BT, Shu XO, Linet MS, Zheng W, Wacholder S, Gao Y, Ying DM, Jin F: Paternal cigarette smoking and the risk of childhood cancer among offspring of nonsmoking mothers. J Natl Cancer Inst 1997, 89:238-244.
8. Shu XO, Ross JA, Pendergrass TW, Reaman GH, Lampkin B, Robison LL: Parental alcohol consumption, cigarette smoking, and risk of infant leukemia: a Childrens Cancer Group study. J Natl Cancer Inst 1996, 88:24-31.
9. Cocco P, Rapallo M, Biddau P, Murgia G, Targhetta R: Age distribution of childhood acute lymphoblastic leukemia cases suggests etiological clues [letter]. Leukemia 1996, 10:1558-1559.
10. Dockerty JD, Cox B, Cockburn MG: Childhood leukaemias in New Zealand: time trends and ethnic differences. Br J Cancer 1996, 73:1141-1147.
11. Schlehofer B, Blettner M, Geletneky K, Haaf HG, Kaatsch P, Michaelis J, Mueller-Lantzsch N, Niehoff D, Winkelspecht B, Wahrendorf J, Schlehofer JR: Sero-epidemiological analysis of the risk of virus infections for childhood leukaemia. Int J Cancer 1996, 65:584-590.
12. Meinert R, Kaatsch P, Kaletsch U, Krummenauer F, Miesner A, Michaelis J: Childhood leukaemia and exposure to pesticides: results of a case-control study in northern Germany. Eur J Cancer 1996, 32A:1943-1948.
13. Dockerty JD, Cox B, Borman B, Sharples K: Population mixing and the incidence of childhood leukaemias: retrospective comparison in rural areas of New Zealand. BMJ 1996, 312:1203-1204.
14. Pui C: Acute leukemia in children. Curr Opin Hematol 1996, 3:249-258.
15. Sawyers CL: Molecular genetics of acute leukemia. Lancet 1997, 349:196-200. A concise review of the molecular abnormalities of ALL and AML, with emphasis on the AML1/CBFb protein complex and the RAS signal transduction pathway.
16. Rubnitz JE, Behm FG, Downing JR: 11q23 rearrangements in acute leukemia. Leukemia 1996, 10:74-82.
17. Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JW, Ratei R, Schrappe M, Repp R, Zimmermann M, Kabisch H, et al.: Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia 1996, 10:957-963. In a prospective study of 673 children with ALL, the BCR-ABL fusion was detected in 3.2% of cases. Although there were no differences in presenting features, this group of patients had a higher incidence of poor responders to prednisone and a worse event-free survival rate.
18. Taki T, Ida K, Bessho F, Hanada R, Kikuchi A, Yamamoto K, Sako M, Tsuchida M, Seto M, Ueda R, Hayashi Y: Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia. Leukemia 1996, 10:1303-1307.
19. Beyermann B, Agthe AG, Adams HP, Seeger K, Linderkamp C, Goetze G, Ludwig WD, Henze G: Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukemia expressing BCR-ABL fusion transcripts. BFM Relapse Study Group. Blood 1996, 87:1532-1538.
20. Rubnitz JE, Behm FG, Curcio-Brint AM, Pinheiro RP, Carroll AJ, Raimondi SC, Shurtleff SA, Downing JR: Molecular analysis of t(11;19) breakpoints in childhood acute leukemias. Blood 1996, 87:4804-4808.
21. Behm FG, Raimondi SC, Frestedt JL, Liu Q, Crist WM, Downing JR, Rivera GK, Kersey JH, Pui CH: Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 1996, 87:2870-2877. This paper demonstrates, for the first time, that MLL gene rearrangement is an unfavorable prognostic factor in patients older than 1 year of age.
22. Mclean TW, Ringold S, Neuberg D, Stegmaier K, Tantravahi R, Ritz J, Koeffler HP, Takeuchi S, Janssen JWG, Seriu T, et al.: TEL/AML1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996, 88:4252-4258. The TEL-AML1 fusion was detected in 27% of childhood ALL cases and was associated with a significantly lower rate of relapse compared to TEL-AML1-negative cases (0/22 versus 16/54). TEL-AML1 formed homodimers in vitro and could also heterodimerize with the normal TEL protein.
23. Rubnitz JE, Downing JR, Pui C, Shurtleff SA, Raimondi SC, Evans WE, Head DR, Crist WM, Rivera GK, Hancock ML, et al.: TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol 1997, 15:1150-1157. In a study of 188 B-precursor ALL cases, TEL gene rearrangements were detected in 48 cases (26%) and were associated with an excellent outcome (91% 5-year EFS). TEL rearrangement was shown to be a favorable prognostic factor independent of age and leukocyte count.
24. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF: Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 1997, 336:317-323. Bone marrow samples from 24 ALL patients were analyzed using quantitative PCR of immunoglobulin gene rearrangement and a clonogenic blast colony assay. Levels of minimal residual disease differed significantly between the 7 patients who relapsed and the 17 who remain in complete remission. In addition, residual PCR positivity was detected in 15 of the 17 patients in remission, up to 35 months after therapy.
25. Wlodarska I, Aventin A, Ingles-Esteve J, Falzetti D, Criel A, Cassiman JJ, Mecucci C, Van Den Berghe H, Marynen P: A new subtype of pre-B acute lymphoblastic leukemia with t(5;12) (q31q33;p12), molecularly and cytogenetically distinct from t(5;12) in chronic myelomonocytic leukemia. Blood 1997, 89:1716-1722.
26. Cimino G, Lanza C, Elia L, Lo Coco F, Gaidano G, Biondi A, Pastore C, Serra A, Canaani E, Croce CM, et al.: Multigenetic lesions in infant acute leukaemias: correlations with ALL-1 gene status. Br J Haematol 1997, 96:308-313.
27. Behm FG, Smith FO, Raimondi SC, Pui CH, Bernstein ID: Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood 1996, 87:1134-1139.
28. Smith FO, Rauch C, Williams DE, March CJ, Arthur D, Hilden J, Lampkin BC, Buckley JD, Buckley CV, Woods WG, et al.: The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. Blood 1996, 87:1123-1133.
29. Corral J, Lavenir I, Impey H, Warren AJ, Forster A, Larson TA, Bell S, McKenzie AN, King G, Rabbitts TH: An MII-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell 1996, 85:853-861. Homologous recombination techniques were used to create chimeric mice that expressed the MII-AF9 fusion under control of the mouse MII promoter. This provided the first formal proof that chromosomal translocations and the resulting fusion genes directly contribute to leukemogenesis.
30. Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, Chan GC, Pui CH, Grosveld G, Downing JR: TEL/AMU fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995, 9:1985-1989.
31. Romana SP, Poirel H, Leconiat M, Flexor MA, Mauchauffe M, Jonveaux P, Macintyre EA, Berger R, Bernard OA: High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 1995, 86:4263-4269.
32. Fears S, Vignon C, Bohlander SK, Smith S, Rowley JD, Nucifora G: Correlation between the ETV6/CBFA2 (TEL/AML1) fusion gene and karyotypic abnormalities in children with B-cell precursor acute lymphoblastic leukemia. Genes Chromosom Cancer 1996, 17:127-135.
33. Liang DC, Chou TB, Chen JS, Shurtleff SA, Rubnitz JE, Downing JR, Pui CH, Shih LY: High incidence of TEL/AML1 fusion resulting from a cryptic t(12; 21) in childhood B-lineage acute lymphoblastic leukemia in Taiwan. Leukemia 1996, 10:991-993.
34. Nakao M, Yokota S, Horiike S, Taniwaki M, Kashima K, Sonoda Y, Koizumi S, Takaue Y, Matsushita T, Fujimoto T, Misawa S: Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia. Leukemia 1996, 10:1463-1470.
35. Shih LY, Chou TB, Liang DC, Tzeng YS, Rubnitz JE, Downing JR, Pui CH: Lack of TEL-AML1 fusion transcript resulting from a cryptic t(12; 21) in adult B lineage acute lymphoblastic leukemia in Taiwan. Leukemia 1996, 10:1456-1458.
36. Raynaud S, Mauvieux L, Cayuela JM, Bastard C, Bilhou-Nabera C, Debuire B, Bories D, Boucheix C, Charrin C, Fiere D, Gabert J: TEL/AML1 fusion gene is a rare event in adult acute lymphoblastic leukemia. Leukemia 1996, 10:1529-1530.
37. Raynaud S, Cave H, Baens M, Bastard C, Cacheux V, Grosgeorge J, Guidal-Giroux C, Guo C, Vilmer E, Marynen P, Grandchamp B: The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia.Blood 1996, 87:2891-2899.
38. Stegmaier K, Takeuchi S, Golub TR, Bohlander SK, Bartram CR, Koeffler HP: Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia. Cancer Res 1996, 56:1413-1417.
39. Romana SP, Le Coniat M, Poirel H, Marynen P, Bernard O, Berger R: Deletion of the short arm of chromosome 12 is a secondary event in acute lymphoblastic leukemia with t(12;21). Leukemia 1996, 10:167-170.
40. Hiebert SW, Sun W, Davis JN, Golub T, Shurtleff S, Buijs A, Downing JR, Grosveld G, Roussell MF, Gilliland DG, et al.: The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol 1996, 16:1349-1355.
41. Okuda T, Van Deursen J, Hiebert SW, Grosveld G, Downing JR: AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996, 84:321-330. Using knockout technology, the authors demonstrate that homozygous disruption of AML1 results in a total absence of definitive hematopoiesis in the mouse.
42. Hangaishi A, Ogawa S, Imamura N, Miyawaki S, Miura Y, Uike N, Shimazaki C, Emi N, Takeyama K, Hirosawa S, et al.: Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood 1996, 87:4949-4958.
43. Marks DI, Kurz BW, Link MP, Ng E, Shuster JJ, Lauer SJ, Brodsky I, Haines DS: High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood 1996, 87:1155-1161.
44. Marks DI, Kurz BW, Unk MP, Ng E, Shuster JJ, Lauer SJ, Carroll D, Brodsky I, Haines DS: Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J Clin Oncol 1997, 15:1158-1162.
45. Cayuela JM, Madani A, Sanhes L, Stern MH, Sigaux F: Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood 1998, 87:2180-2186.
46. Nakao M, Yokota S, Kaneko H, Seriu T, Koizumi S, Takaue Y, Fujimoto T, Misawa S: Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: mutations of CDKN2 are observed preferentially in T lineage. Leukemia 1996, 10:249-254.
47. Iolascon A, Faienza MF, Coppola B, Della Ragione F, Schettini F, Biondi A: Homozygous deletions of cyclin-dependent kinase inhibitor genes, P16INK4A and p18, in childhood T cell lineage acute lymphoblastic leukemias. Leukemia 1996, 10:255-260.
48. Ohnishi H, Hanada R, Horibe K, Hongo T, Kawamura M, Naritaka S, Bessho F, Yanagisawa M, Nobori T, Yamamori S, Hayashi Y: Homozygous deletions of p16/MTS1 and p15/MTS2 genes are frequent in t(1;19)-negative but not in t(1;19)-positive B precursor acute lymphoblastic leukemia in childhood. Leukemia 1996, 10:1104-1110.
49. Heyman M, Rasool O, Borgonovo Brandter L, Liu Y, Grander D, Soderhall S, Gustavsson G, Einhorn S: Prognostic importance of p15INK4B and P16INK4 gene inactivation in childhood acute lymphocytic leukemia. J Clin Oncol 1996, 14:1512-1520.
50. Cayuela JM, Baruchel A, Orange C, Madani A, Auclerc MF, Daniel MT, Schaison G, Sigaux F: TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia. Blood 1996, 88:302-308.
51. Cimino G, Elia L, Rivolta A, Rapanotti MC, Rossi V, Alimena G, Annino L, Canaani E, Lo Coco F, Biondi A: Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF-4 positive-acute lymphoblastic leukaemia. Br J Haematol 1996, 92:659-664.
52. Privitera E, Rivolta A, Ronchetti D, Mosna G, Giudici G, Biondi A: Reverse transcriptase/polymerase chain reaction follow-up and minimal residual disease detection in t(1;19)-positive acute lymphoblastic leukaemia. Br J Haematol 1996, 92:653-658.
53. Preudhomme C, Henic N, Cazin B, Lai JL, Bertheas MF, Vanrumbeke M, Lemoine F, Jouet JP, Deconninck E, Nelken B, et al.: Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL). Leukemia 1997, 11:294-298.
54. Lanza C, Gottardi E, Gaidano G, Vivenza C, Parziale A, Perfetto F, Fornaci M, Barisone E, Madon E, Basso G, Saglio G: Persistence of E2A/PBX1 transcripts in t(1;19) childhood acute lymphoblastic leukemia: correlation with chemotherapy intensity and clinical outcome. Leuk Res 1996, 20:441-443.
55. Wu NH, Lu SG, Zhu P, Peng YY: Detection of minimal residual disease in childhood acute lymphoblastic leukemia after termination of therapy. Pediatr Hematol Oncol 1996, 13:257-263.
56. Inoue K, Ogawa H, Yamagami T, Soma T, Tani Y, Takekawa T, Oji Y, Tamaki H, Kyo T, Dohy H, et al.: Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996, 88:2267-2278.
57. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, Miyake S, Tamaki H, Oji Y, Tamagami T, et al.: Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997, 89:1405-1412. Aberrant overexpression of WT1 was seen in leukemic blasts, but not in normal hematopoietic progenitor cells, implicating WT1 in the development of leukemia and also providing a marker to monitor MRD.
58. 9/L were considered standard risk and had a 4-year EFS of 80%. All others were considered high-risk and had a 65% 4-year EFS.
59. Pui CH, Ribeiro RC, Campana D, Raimondi SC, Hancock ML, Behm FG, Sanlund JT, Rivera GK, Evans WE, Crist WM, Krance R: Prognostic factors in the acute lymphoid and myeloid leukemias of infants. Leukemia 1996, 10:952-956.
60. Rubnitz JE, Shuster JJ, Land VJ, Link MP, Pullen DJ, Camitta BM, Pui C, Downing JR, Behm FG: Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study. Blood 1997, 89:1143-1146. A retrospective study of 104 patients suggested that the favorable prognosis impact of TEL gene rearrangements extends to patients treated with conventional antimetabolite-based therapy.
61. Raimondi SC, Pui CH, Hancock ML, Behm FG, Filatov L, Rivera GK: Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. Leukemia 1996, 10:213-224.
62. Gajjar A, Ribeiro RC, Mahmoud HH, Sandlund JT, Liu Q, Furman WL, Santana VM, Crist WM, Rivera GK, Pui CH: Overt testicular disease at diagnosis is associated with high risk features and a poor prognosis in patients with childhood acute lymphoblastic leukemia. Cancer 1996, 78:2437-2442.
63. Uckun FM, Steinherz PG, Sather H, Trigg M, Arthur D, Tubergen D, Gaynon P, Reaman G: CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 1996, 88:4288-4295.
64. Kumagai M, Manabe A, Pui CH, Behm FG, Raimondi SC, Hancock ML, Mahmoud H, Crist WM, Campana D: Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest 1996, 97:755-760.
65. Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Chappell R, et al.: Cytoreduction and prognosis in acute lymphoblastic leukemia-the importance of early marrow response: report from the Childrens Cancer Group [see comments]. J Clin Oncol 1996, 14:389-398.
66. Pui C: Acute lymphoblastic leukemia. Pediatr Clin North Am 1997. In press.
67. Childhood ALL Collaborative Group: Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12,000 randomised children. Lancet 1996, 347:1783-1788. This large meta-analysis of 42 ALL trials demonstrated that total adverse events were significantly reduced by longer maintenance, vincristine-prednisone pulse therapy, and intensive reinduction, but overall patient survival was improved only by intensive reinduction.
68. Sorensen K, Levin G, Chessells J, Sullivan I: Anthracycline dose in childhood acute lymphoblastic leukemia: Issues of early survival versus late cardiotoxicity. J Clin Oncol 1997, 15:61-68.
69. Winick N, Shuster JJ, Bowman WP, Borowitz M, Farrow A, Jacaruso D, Buchanan GR, Kamen BA: Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. J Clin Oncol 1996, 14:2803-2811.
70. Lange BJ, Blatt J, Sather HN, Meadows AT: Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study. Med Pediatr Oncol 1996, 27:15-20.
71. Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, Pui CH, Evans WE: Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 1996, 97:73-80. In a randomized study of 150 newly diagnosed patients, ALL blasts accumulated higher concentrations of methotrexate polyglutamates after treatment with high-dose methotrexate compared with lower-dose methotrexate. Higher methotrexate polyglutamate levels were also associated with greater antileukemic effects in vivo.
72. Freeman AI, Boyett JM, Glicksman AS, Brecher ML, Leventhal BG, Sinks LF, Holland JF: Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up. Med Pediatr Oncol 1997, 28:89-107.
73. Veerman AJ, Hahlen K, Kamps WA, Van Leeuwen EF, De Vaan GA, Solbu G, Suciu S, Van Wering ER, Van Der Does-Van Der Berg A: High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 1996, 14:911-918. This study of 190 uniformly treated non-high-risk ALL patients reported an 8-year EFS of 81% and a CNS relapse rate of only 1.1%, suggesting a role for dexamethasone in preventing CNS relapse.
74. Ito C, Evans WE, McNinch L, Coustan-Smith E, Mahmoud H, Pui CH, Campana D: Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol 1996, 14:2370-2376.
75. Kaspers GJ, Veerman AJ, Popp-Snijders C, Lomecky M, Van Zantwijk CH, Swinkels LM, Van Werig ER, Pieters R: Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1996, 27:114-121.
76. Cherlow JM, Sather H, Steinherz P, Gaynon P, Tubergen D, Trigg M, Novak L, Bleyer WA: Craniospinal irradiation for acute lymphoblastic leukemia with central nervous system disease at diagnosis: a report from the Children's Cancer Group [see comments]. Int J Radiat Oncol Biol Phys 1996, 36:19-27. In a study of 53 patients with overt CNS disease at diagnosis, intensive systemic and intrathecal chemotherapy combined with craniospinal irradiation produced excellent results, with a 5-year EFS that was similar to that for patients without CNS disease (69% versus 67%). In addition, 6 Gy was an adequate dose of spinal irradiation.
77. Kun LE: CNS disease at diagnosis: a continuing challenge in childhood lymphoblastic leukemia [editorial; comment]. Int J Radiat Oncol Biol Phys 1996, 36:257-259.
78. Sackmann-Muriel F, Felice MS, Zubizarreta P, Chantada G, Barbieri MAF, Rossi J: Improved outcome in higher-risk acute lymphoblastic leukemia with a hybrid (Berlin-Frankfurt-Munster/St. Jude's) therapy. Int J Pediatr Hematol/Oncol 1996, 3:439-449.
79. Koizumi S, Fujimoto T, Oka T, Watanabe S, Kikuta A, Tsuchiya T, Matsushita T, Asami K, Yanase T, Mimaya J, et al.: Overview of clinical studies of childhood acute lymphoblastic leukemia for more than ten years by the Japanese Children's Cancer and Leukemia Study Group. Pediatr Hematol Oncol 1997, 14:17-28.
80. Matsuzaki A, Ishii E, Okamura J, Eguchi H, Yoshida N, Yanai F, Inoue T, Miyake K, Ishihara T, Tsuboi C, et al.: Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan. Med Pediatr Oncol 1996, 26:10-19.
81. Buendia MTA, Terselich G, Lozano JM, Viscaino MP: Acute lymphoblastic leukemia in children: nonrandomized comparison of conventional vs. intensive chemotherapy at the National Cancer Institute of Colombia. Med Pediatr Oncol 1997, 28:108-116.
82. Aziz Z, Zahid M, Mahmood R, Maqbool S: Modified BFM protocol for childhood acute lymphoblastic leukemia: a retrospective analysis. Med Pediatr Oncol 1997, 28:48-53.
83. Pui C, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT, Synold T, Relling MV, Ribeiro RC, Crist WM, Evans WE: Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997. In press. In a randomized study of 164 newly diagnosed ALL patients, G-CSF treatment produced modest clinical benefits, but did not result in a lower hospitalization rate for febrile neutropenia, a reduction in cost of supportive care, or a survival benefit.
84. Welte K, Reiter A, Mempel K, Pfetsch M, Schwab G, Schrappe M, Riehm H: A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group. Blood 1996, 87:3143-3150.
85. Mitchell PLR, Morland B, Stevens MCG, Dick G, Eaqslea D, Meyer LC, Pinkerton CR: Granulocyte colony-stimulating factor in established febrile neutropenia: A randomized study of pediatric patients. J Clin Oncol 1997, 15:1163-1170.
86. Saarinen UM, Mellander L, Nysom K, Ringden O, Schroeder H, Glomstein A, Gustafsson G: Allogeneic bone marrow transplantation in first remission for children with very high-risk acute lymphoblastic leukemia: a retrospective case-control study in the Nordic countries. Nordic Society for Pediatric Hematology and Oncology (NOPHO). Bone Marrow Transplant 1996, 17:357-363.
87. Uderzo C, Valsecchi MG, Balduzzi A, Dini G, Miniero R, Locatelli F, Rondelli R, Pession A, Arcese W, Bacigalupo A, et al.: Allogeneic bone marrow transplantation versus chemotherapy in high-risk childhood acute lymphoblastic leukaemia in first remission. Br J Haematol 1997, 96:387-394.
88. Dunlop LC, Powles R, Singhal S, Treleaven JG, Swansbury GJ, Meller S, Pinkerton CR, Horton C, Mehta J: Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1996, 17:365-369.
89. Appelbaum FR: Allogeneic hematopoietic stem cell transplantation for acute leukemia. Semin Oncol 1997, 24:114-123.
90. 9/L had outcomes similar to that for patients without the Philadelphia chromosome.
91. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR: Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1997, 335:1041-1048.
92. Bertino JR, Goker E, Gorlick R, Li WW, Banerjee D: Resistance mechanisms to methotrexate in tumors. Oncologist 1996, 1:223-226.
93. Gorlick R, Goker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar M, Flintoff WF, Bertino JR: Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997, 89:1013-1018. Defective methotrexate transport was seen in more than 70% of relapsed ALL cases compared to only 13% of untreated patients. Moreover, impaired transport was associated with decreased reduced folate carrier expression.
94. Spencer HT, Sorrentino BP, Pui CH, Chunduru SK, Sleep SE, Blakley RL: Mutations in the gene for human dihydrofolate reductase: an unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate. Leukemia 1996, 10:439-446.
95. Stromhaug A, Slordal L, Warren DJ: Differential effects of the antifolates methotrexate, aminopterin and trimetrexate on murine haemopoietic progenitor cells. Br J Haematol 1996, 92:514-520.
96. Ivy SP, Olshefski RS, Taylor BJ, Patel KM, Reaman GH: Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study. Blood 1996, 88:309-318.
97. Volm M, Zintl F, Edler L, Sauerbrey A: Prognostic value of protein kinase C, proto-oncogene products and resistance-related proteins in newly diagnosed childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1997, 28:117-126.
98. Rivera GK, Hudson MM, Liu Q, Benaim E, Ribeiro RC, Crist WM, Pui CH: Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. Blood 1996, 88:831-837.
99. Buhrer C, Hartmann R, Fengler R, Rath B, Schrappe M, Janka-Schaub G, Henze G: Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Munster Relapse Study Group. J Clin Oncol 1996, 14:2812-2817.
100. Oakhill A, Pamphilon DH, Potter MN, Steward CG, Goodman S, Green A, Goulden P, Goulden NJ, Hale G, Waldmann H, Cornish JM: Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996, 94:574-578.
101. Davies SM, Wagner JE, Shu XO, Blazar BR, Katsanis E, Orchard PJ, Kersey JH, Dusenbery KE, Wiesdorf DJ, McGlave PB, Ramsay NKC: Unrelated donor marrow transplantation for children with acute leukemia. J Clin Oncol 1997, 15:557-565.
102. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, Ciocci G, Carrier C, Stevens CE, Rubinstein P: Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996, 335:157-166. Twenty-three of 25 patients who received placental blood demonstrated engraftment of the infused hematopoietic stem cells, suggesting that placental blood may be a viable alternative source of stem cells for the treatment of childhood malignancies.
103. Parsons SK, Castellino SM, Lehmann LE, Eickhoff CE, Tarbell NJ, Sallan SE, Weinstein HJ, Billett AL: Relapsed acute lymphoblastic leukemia: similar outcomes for autologous and allogeneic marrow transplantation in selected children. Bone Marrow Transplant 1996, 17:763-768.
104. Vervoordeldonk SF, Merle PA, Behrendt T, Steenbergen EJ, Van Den Berg H, Van Wering ER, Von Dem Borne AE, Van Der Schoot CE, Van Leeuwen EF, Slaper-Cortenbach IC: PCR-positivity in harvested bone marrow predicts relapse after transplantation with autologous purged bone marrow in children in second remission of precursor B-cell acute leukaemia. Br J Haematol 1997, 96:395-402.
105. Collins RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, et al.: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15:433-444.
106. Messina C, Zambello R, Rossetti F, Gazzola MV, Varotto S, Destro R, Basso G, Semenzato G, Zanesco L: Interleukin-2 before and/or after autologous bone marrow transplantation for pediatric acute leukemia patients. Bone Marrow Transplant 1996, 17:729-735.
107. Foa R: Interleukin 2 in the management of acute leukaemia. Br J Haematol 1996, 92:1-8.
108. Mitchell PLR, Clutterbuck RD, Powles RL, De Lord C, Morilla R, Hiorns LR, Titley J, Catovsky D, Millar JL: Interleukin-4 enhances the survival of severe combined immunodeficient mice engrafted with human B-cell precursor leukemia. Blood 1996, 87:4797-4803.